CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Inclusion Criteria: * Signed ICF (Informed Consent Form) and HIPAA (Health Insurance Portability and Accountability Act) * Patient-reported history of DED in both eyes * Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms * Ability and willingness to follow instructions, including participation in all study assessments and visits Exclusion Criteria: * Women who are pregnant, nursing or planning a pregnancy * Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control * Clinically significant slit-lamp findings or abnormal lid anatomy at screening * Ocular/periocular malignancy * History of herpetic keratitis * Active ocular allergies or ocular allergies that may become active during the study period * Ongoing ocular or systemic infection at screening or baseline * Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study * History of no response to previous topical Cyclosporine A and/or use of topical Cyclosporine A or Liftigrast within 2 months prior to screening * Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period * Presence of uncontrolled systemic diseases * Presence of known allergy and/or sensitivity to the study drug or its components